The Conversation (0)
Ember Therapeutics, Inc. (OTCQB:EMBT), a New York-based pharmaceutical company developing targeted therapies for osteoarthritis, kidney fibrosis, and other regenerative medicines, today announced that it has entered into a definitive agreement for the acquisition of Migralex™, a commercially available over-the-counter medication for treating pain.
Ember Therapeutics, Inc. (OTCQB:EMBT), a New York-based pharmaceutical company developing targeted therapies for osteoarthritis, kidney fibrosis, and other regenerative medicines, today announced that it has entered into a definitive agreement for the acquisition of Migralex™, a commercially available over-the-counter medication for treating pain.
According to the news:
As part of the transaction, all assets from Migralex, Inc. will be transferred to Ember Therapeutics, Inc.
Joseph Hernandez, Executive Chairman of Ember Therapeutics, Inc. commented:
This is our second acquisition this quarter. The addition of a great brand, such as Migralex™, to our pipeline will allow us to provide relief to over 150 million Americans suffering from recurrent pain. Furthermore, as Migralex™ is a commercial stage asset, the revenue generated by this product will help further the development of our two Phase 3 ready clinical programs in osteoarthritis and regenerative medicine.